Google
SLP 株価分析 — SIMULATIONS PLUS INC (Healthcare >> Health Information Services)
SLP に関するよくある質問
SLPのPER（株価収益率）は？
SIMULATIONS PLUS INC（SLP）は現在PER 42.13倍で取引されています。
SLPのROE（自己資本利益率）は？
SIMULATIONS PLUS INCのROEは5.83%です。
SLPの配当利回りは？
SIMULATIONS PLUS INCの配当利回りは0.00%です。
SLPの品質スコア（Quality Score）は？
当社のAIはSLPの総合財務品質を100点中31点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
SLPは今が買い時ですか？
当社AIのタイミングスコアは100点中87点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
SLPはどのセクターに属しますか？
SIMULATIONS PLUS INCはHealthcare >> Health Information Servicesセクターに分類されます（NASDAQ市場）
SLP AI Analysis Summary
Our AI summary for SLP: SIMULATIONS PLUS INC (NASDAQ), Healthcare >> Health Information Services sector. The stock currently trades at a P/E of 42.13, ROE of 5.83%, a dividend yield of 0.00%. Its financial Quality Score stands at 31/100 — fundamentals below the market average. The AI Timing Score is 87/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 18.23
Price
-0.07
(-0.38%)
Day Change
|
|
|---|
SLP, ファンダメンタルスコアはnot good ( ファンダメンタル = 31) but テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROEの伸びが低い
平均ROEが低い
昨年度のROEが一昨年比で低い
ROAの伸びが低い
Last-year ROA is lower than last-2-years ROA.
NPMが低い
NPMの伸びが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...
| Deepscope 分析 |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 69 |
| Magic Formula Rank by ROA |
436
|
| Magic Formula Rank by ROE |
436
|
| Magic Formula Rank by ROIC |
425
|
| Price | 18.23 |
| PBV / Sector |
2.66 / 6.33
|
| Earning Per Share | 0.40 |
| PE / Sector |
42.13 / 46.50
|
| PEG or PE/Growth / Sector |
-0.16 / -0.41
|
| Average 1M Daily Value |
8.63 M
|
| Average 1W Daily Value |
5.44 M
GREAT
|
| Timing Factors |
|
57% |
| Financial Health |
|
41% |
| ポイントになる統計 |
|
52% |
| 配当 |
|
41% |
| 登録情報 |
| Analyze Date | 2026-08-01 08:00:29 |
| Symbol | SLP |
| Name | SIMULATIONS PLUS INC |
| Sector | Healthcare >> Health Information Services |
| Market | NASDAQ |
| Listed Shares | 20.22 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 370.11 / 4,079.00 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 800 Park Offices Drive, Research Triangle Park, NC, United States, 27709
Phone: 661 723 7723
Website: https://www.simulations-plus.com
Employees: 212
Description: Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. It operates through Software and Services segments. The company offers GastroPlus, which predicts absorption, biopharmaceutics, pharmacokinetics, and pharmacodynamics in humans and animals; and DDDPlus and MembranePlus simulation products. It also provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, OBESITYsym, and Thales products. In addition, the company offers Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Further, it provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Additionally, the company offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Research Triangle Park, North Carolina.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Health Information Services
Click a bubble to view stock details · Bubble size represents market capitalization share
